WO2018053275A1 - Utilisation de pridopidine pour traiter la dysautonomie familiale - Google Patents

Utilisation de pridopidine pour traiter la dysautonomie familiale Download PDF

Info

Publication number
WO2018053275A1
WO2018053275A1 PCT/US2017/051798 US2017051798W WO2018053275A1 WO 2018053275 A1 WO2018053275 A1 WO 2018053275A1 US 2017051798 W US2017051798 W US 2017051798W WO 2018053275 A1 WO2018053275 A1 WO 2018053275A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
pridopidine
amount
pharmaceutical composition
elevating
Prior art date
Application number
PCT/US2017/051798
Other languages
English (en)
Inventor
Adrian Gilbert
Gil Ast
Michal Geva
Original Assignee
Teva Pharmaceuticals International Gmbh
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International Gmbh, Teva Pharmaceuticals Usa, Inc. filed Critical Teva Pharmaceuticals International Gmbh
Publication of WO2018053275A1 publication Critical patent/WO2018053275A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine

Abstract

L'invention concerne un procédé de traitement de la dysautonomie familiale d'un sujet le nécessitant, consistant à administrer périodiquement au sujet une composition pharmaceutique comprenant une quantité de pridopidine efficace pour traiter le sujet.
PCT/US2017/051798 2016-09-16 2017-09-15 Utilisation de pridopidine pour traiter la dysautonomie familiale WO2018053275A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662395998P 2016-09-16 2016-09-16
US62/395,998 2016-09-16
US201762544320P 2017-08-11 2017-08-11
US62/544,320 2017-08-11

Publications (1)

Publication Number Publication Date
WO2018053275A1 true WO2018053275A1 (fr) 2018-03-22

Family

ID=61618935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/051798 WO2018053275A1 (fr) 2016-09-16 2017-09-15 Utilisation de pridopidine pour traiter la dysautonomie familiale

Country Status (1)

Country Link
WO (1) WO2018053275A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322119B2 (en) 2013-06-21 2019-06-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating Huntington's disease
US10799492B2 (en) 2010-09-03 2020-10-13 Prilenia Neurotherapeutics Ltd. Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11000519B2 (en) 2017-09-08 2021-05-11 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11207310B2 (en) 2016-08-24 2021-12-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US11826361B2 (en) 2016-08-24 2023-11-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130310404A1 (en) * 2010-10-13 2013-11-21 Horacio Uri Saragovi Inhibitors of p75 receptor and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130310404A1 (en) * 2010-10-13 2013-11-21 Horacio Uri Saragovi Inhibitors of p75 receptor and their uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEISHVILI ET AL.: "IKAP/Elp1 involvement in cytoskeleton regulation and implication for familial dysautonomia", HUMAN MOLECULAR GENETICS, vol. 20, no. 8, 15 April 2011 (2011-04-15), pages 1585 - 1594, XP055489493 *
GEVA ET AL.: "Pridopidine activates neuroprotective pathways impaired in Huntington Disease", HUMAN MOLECULAR GENETICS, vol. 25, no. 18, 27 July 2016 (2016-07-27), pages 3975 - 3987, XP055489491 *
KEREN ET AL.: "Phosphatidylserine Increases IKBKAP Levels in Familial Dysautonomia Cells", PLOS ONE, vol. 5, no. 12, 29 December 2010 (2010-12-29), pages 1 - 12, XP055209240 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799492B2 (en) 2010-09-03 2020-10-13 Prilenia Neurotherapeutics Ltd. Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US10322119B2 (en) 2013-06-21 2019-06-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating Huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11207310B2 (en) 2016-08-24 2021-12-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US11826361B2 (en) 2016-08-24 2023-11-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
US11000519B2 (en) 2017-09-08 2021-05-11 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias

Similar Documents

Publication Publication Date Title
WO2018053275A1 (fr) Utilisation de pridopidine pour traiter la dysautonomie familiale
AU2019203448B2 (en) Fenfluramine for use in the treatment of dravet syndrome
ES2764480T3 (es) Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato
CA3079259A1 (fr) Ganaxolone destinee a etre utilisee dans le traitement de troubles epileptiques genetiques
AU2017326013B2 (en) Use of pridopidine for treating Rett syndrome
US20210401776A1 (en) Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
EP2063892A2 (fr) Méthodes et compositions de traitement de la sclérose latérale amyotrophique (sla)
EP3193907B1 (fr) Procédé de traitement de syndrome prader-willi
EP3930841A1 (fr) Formulation pour améliorer le contrôle des crises d'épilepsie
US20160193231A1 (en) Rett syndrome and treatments therefore
JP5159779B2 (ja) 糖尿病および神経心理学的機能不全を処置するための組成物および方法
US20230096920A1 (en) Treatment of demyelinating diseases
US10660957B2 (en) Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject
US11241434B2 (en) Compositions and methods for improving cognition in a subject
EP3582764B1 (fr) Traitement d'un trouble lié à la consommation d'alcool
US20200281928A1 (en) Vitamin b1 in high doses for use in the medical treatment of motor symptoms of some sporadic neurodegenerative diseases, of genetic origin, and of cluster headache and of migraine headache
US11730769B2 (en) Compositions and methods for Williams Syndrome (WS) therapy
CN114652722A (zh) 一种化合物在制备治疗Alport综合征的药物中的应用
WO2017070731A1 (fr) Compositions et méthodes pour le traitement de la maladie d'alzheimer
Kurita et al. Novel Targets for Drug Treatment in Psychiatry
WO2011000564A1 (fr) Eltoprazine pour le traitement de la pharmacodépendance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17851610

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17851610

Country of ref document: EP

Kind code of ref document: A1